Ablynx

@AblynxABLX

Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies® for a range of serious human diseases.

Ghent/Zwijnaarde, Belgium
Připojil se květen 2012

Tweety

Zablokovali jste uživatele @AblynxABLX.

Opravdu chcete tyto tweety zobrazit? Zobrazením tweetů nedojde k odblokování uživatele @AblynxABLX.

  1. Retweetnuto uživatelem
    26. 7.

    FDA designates top nanobody caplacizumab fast track designation: 6-10 months faster approval

  2. Retweetnuto uživatelem
    20. 7.
  3. 20. 7.

    and Sanofi to develop up to 8 Nanobody®-based therapeutics focused on immuno-inflammatory diseases

  4. 27. 6.

    achieves second milestone in immuno-oncology collaboration with Merck & Co., Inc.

  5. 26. 6.

    initiates a single and multiple dose Phase I study of caplacizumab in healthy Japanese subjects

  6. 29. 5.

    launches , a new website dedicated to Thrombotic Thrombocytopenic Purpura (TTP)

  7. 22. 5.

    receives €15M milestone from Merck KGaA for novel Nanobody in osteoarthritis

  8. 18. 5.

    Meet our experts and recruiters (booth 99) @

  9. 11. 5.
  10. 11. 5.

    Q1 2017 "Positive start of the year; good progress in multiple programmes; strong cash position"

  11. 10. 5.

    Publication in Journal of Thrombosis and Haemostasis "Caplacizumab reduces major thromboembolic events"

  12. 2. 5.

    successfully completes patient recruitment in its Phase III Hercules study of caplacizumab

  13. 7. 4.

    Annual Report 2016 is available online - view via

  14. 7. 4.
  15. Retweetnuto uživatelem
    6. 3.

    Compelling data for developed psoriasis nanobody in collaboration

  16. Retweetnuto uživatelem
    28. 2.

    Good morning to those waking up in Europe, Africa and the Middle East! Share with us what you have planned for today!

  17. Retweetnuto uživatelem
    24. 2.

    you will find out that is dedicated to creating new medicines which will make a real difference to society!

  18. 23. 2.

    FYR 2016: significant progress in R&D pipeline; strong cash position; major catalysts in 2017.

  19. 9. 2.

    will present additional data from the Phase IIb RA combination study of vobarilizumab at the Annual CRA Meeting

  20. 6. 2.

Načítání se zjevně nějak vleče.

Možná je překročena kapacita Twitteru nebo došlo k momentálnímu zablokování. Zkuste to znovu nebo se podívejte na stavovou stránku Twitteru, kde najdete další informace.

    Také by se vám mohlo líbit

    ·